Edwards Lifesciences (EW) Stock
Heart valve and critical care monitoring leader. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in September 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It’s Moving
Edwards Lifesciences gets a policy boost as investors focus on growth momentum
- CMS expanded TAVR coverage, which could broaden access for Edwards Lifesciences’ core heart-valve procedures and support demand across its flagship franchise.
- The company’s recent second-quarter results beat expectations, with stronger sales and EPS, reinforcing confidence that growth is still running ahead of consensus.
- Investors are also weighing the company’s reaffirmed 2026 guidance and the upcoming healthcare summit appearance, which may keep attention on near-term execution and commentary.
Edwards Lifesciences gets a policy boost as investors focus on growth momentum
- CMS expanded TAVR coverage, which could broaden access for Edwards Lifesciences’ core heart-valve procedures and support demand across its flagship franchise.
- The company’s recent second-quarter results beat expectations, with stronger sales and EPS, reinforcing confidence that growth is still running ahead of consensus.
- Investors are also weighing the company’s reaffirmed 2026 guidance and the upcoming healthcare summit appearance, which may keep attention on near-term execution and commentary.
Sixth Month Growth Performance
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
The next expected earnings date for EW is October 29, 2026, based on the current reporting schedule. This release should cover Q3 2026 results. If the company shifts timing slightly, the report has historically been expected in late October.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Edwards Lifesciences' stock with a target price of $91.81, indicating growth potential.
Financial Health
Edwards Lifesciences is doing well with strong profits, cash flow, and high revenue levels.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
